Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
POLR2KP1 is a pseudogene related to the POLR2K gene, which encodes subunit K of the RNA polymerase II enzyme complex. Unlike functional RNA polymerase II subunits that participate directly in transcription, pseudogenes like POLR2KP1 do not encode a functional protein product and are generally considered transcriptionally inactive or non-functional. The POLR2K subunit itself is one of several small subunits critical for RNA polymerase II assembly and activity[1]; however, the pseudogene POLR2KP1 does not perform any known cellular function. Key points: - POLR2KP1 is not a therapeutic target and is not functionally equivalent to POLR2K or other RNA polymerase II subunits. - POLR2KP1 is a pseudogene; in human genome annotation, pseudogenes are genomic DNA sequences similar to normal genes but nonfunctional. - There is no evidence for drug interactions, biomarker roles, or safety concerns related to POLR2KP1. - All documented disease roles and molecular classifications for RNA polymerase II subunits (such as POLR2C or POLR2K) do not apply to the pseudogene POLR2KP1[1][2][6].
None (no mechanism of drug action due to lack of protein expression/function)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA polymerase II subunit K pseudogene 1 (POLR2KP1).